Octreotide LA is under clinical development by Camurus and currently in Phase III for Neuroendocrine Tumors. According to GlobalData, Phase III drugs for Neuroendocrine Tumors have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Octreotide LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Octreotide LA overview
Octreotide long-acting (CAM-2029) is under development for the treatment of gastroenteropancreatic neuroendocrine tumor, polycystic liver disease, acromegaly and neuroendocrine tumors with carcinoid symptoms. It is administered through subcutaneous route. It acts by targeting somatostatin receptor (SSTR2 and SSTR5). The drug candidate is a next-generation octreotide depot and it is developed based on FluidCrystal injectable depot technology.
It was also under development for the treatment of coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome and polycystic kidney disease.
Camurus overview
Camurus, a subsidiary of Sandberg Development AB, is a pharmaceutical company that develops and commercializes treatments for patients suffering from chronic diseases. The company’s major products include CAM2038 to treat chronic pain; CAM2029 to treat acromegaly, GEP-NET and PLD; CAM4072 to treat genetic obesity disorders; CAM2032 to treat Prostate cancer; CAM2043 to treat pulmonary arterial hypertension and Raynaud’s phenomenon; CAM4071 to treat endocrine disorders; bridal drug candidates. It markets drugs under the brand name of Episil, FluidCrystal. The company has developmental and commercial collaborations with biotechnology and pharmaceutical companies for product development. Camurus is headquartered in Lund, Sweden.
For a complete picture of Octreotide LA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
